ORLANDO, FL - Nutriband Inc. (NASDAQ:NTRB), a pharmaceutical company specializing in transdermal drug delivery systems, announced today a share repurchase program. The company plans to buy back up to $1,000,000 of its common stock, signaling confidence in its financial health and future prospects.
The repurchase initiative comes as Nutriband continues to make progress on its leading product, AVERSA Fentanyl, an abuse-deterrent fentanyl patch. This product is designed to incorporate the company's proprietary AVERSA technology, aimed at preventing drug abuse and misuse. Nutriband holds to its timeline of submitting a New Drug Application (NDA) to the FDA in the first or second quarter of 2025.
Nutriband's current share structure includes 11,106,185 shares of common stock outstanding as of today. The buyback program is a strategic move that could potentially benefit shareholders by reducing the number of shares available on the market, which might lead to an increase in the value of remaining shares.
The development of the AVERSA Fentanyl patch is particularly significant for Nutriband, as it represents an innovative approach to addressing the opioid crisis by deterring abuse of transdermal fentanyl. While the company is optimistic about the potential of its abuse-deterrent technology, it acknowledges the inherent risks and uncertainties associated with the development and regulatory approval of new pharmaceutical products.
Nutriband's forward-looking statements in the press release reflect the company's expectations and are subject to risks and uncertainties. These statements are not guarantees of future performance, and actual results may differ materially due to various factors, including the challenges of developing new products, securing patent protection, obtaining necessary financing and regulatory approvals, and successfully marketing its products.
This announcement is based on a press release statement and provides a snapshot of Nutriband's current corporate activities and strategic direction. Investors and stakeholders are advised to consider the company's public filings with the Securities and Exchange Commission for a comprehensive understanding of the risks involved.
In other recent news, Nutriband Inc. is making significant strides in the development of its AVERSA™ technology, an anti-abuse patch system. The company is nearing the acquisition of a trademark for this technology, having received a Notice of Allowance from the United States Patent and Trademark Office. In collaboration with Kindeva Drug Delivery, Nutriband is also advancing the commercial-scale manufacturing process for AVERSA™ Fentanyl, its flagship product.
In the context of recent developments, Nutriband is planning to conduct a human abuse potential clinical study, a crucial step before filing a New Drug Application with the FDA. Additionally, Nutriband recently appointed Sergei Glinka to its board of directors following his $4.5 million investment, which is expected to support the FDA approval process for the AVERSA™ technology.
Moreover, Nutriband secured $8.4 million in a private placement funding round to advance AVERSA™ Fentanyl. Market analysis by Health Advances suggests that AVERSA™ Fentanyl could achieve peak annual sales between $80 million and $200 million in the U.S. market. These developments highlight Nutriband's ongoing efforts to combat drug abuse and misuse through innovative pharmaceutical solutions.
InvestingPro Insights
Nutriband Inc. (NASDAQ:NTRB) has recently shown a mix of financial and market performance indicators that may be of interest to current and potential investors. According to InvestingPro data, Nutriband has a market capitalization of approximately $48.74 million. Despite a challenging revenue growth environment in the last twelve months as of Q2 2025, with a revenue decline of 20.83%, the company has managed to maintain a gross profit margin of 33.62%, indicating a degree of cost management efficiency.
InvestingPro Tips highlight that Nutriband holds more cash than debt on its balance sheet, which can be a sign of financial stability, and analysts anticipate sales growth in the current year. This could suggest that Nutriband's strategic initiatives, such as the share repurchase program and the development of AVERSA Fentanyl, might be aligning with broader market expectations for future growth. However, it's worth noting that the company has not been profitable over the last twelve months, which is reflected in its negative P/E ratio of -5.66.
Market performance data shows significant volatility in Nutriband's stock price, with a notable return of 64.94% over the last year and an impressive year-to-date price total return of 92.67%. This volatility is further evidenced by the stock's price being at 46.02% of its 52-week high. Investors interested in the dynamics behind these figures can find an additional 8 InvestingPro Tips for Nutriband at https://www.investing.com/pro/NTRB, providing deeper insights into the company's performance and potential investment considerations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.